Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Clin Cancer Res
    March 2026
  1. BUTT OH, Singhal K, Luo J, Rettig MP, et al
    NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomas.
    Clin Cancer Res. 2026 Mar 25. doi: 10.1158/1078-0432.CCR-25-2953.
    >> Share

  2. SANVITO F, Raymond C, Telesca D, Yao J, et al
    Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial.
    Clin Cancer Res. 2026 Mar 16. doi: 10.1158/1078-0432.CCR-25-4419.
    >> Share

  3. FUKUMURA K, Jiang P, Yeboa DN, Singareeka Raghavendra A, et al
    Ionizing radiation enhances prognostically significant cellular immunity programs in the brain metastasis microenvironment.
    Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-3525.
    >> Share

  4. CROWELL C, Mankuzhy NP, Bennett J, Bandopadhayay P, et al
    Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3764.
    >> Share

  5. RICCI AD, Rizzo A
    Unlocking New Possibilities: Dual Immune Blockade in Brain Metastases from Rare Tumors.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-4816.
    >> Share

    February 2026
  6. CHEN J, Oberheim Bush NA, Grabowsky JA, Kline C, et al
    A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma.
    Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-4080.
    >> Share

  7. PROST D, Nichelli L, Rozenblum L, Laurenge A, et al
    18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors.
    Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-0279.
    >> Share

    January 2026
  8. ENE CI, Singh S, Venkataraman T, Phillips LM, et al
    Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).
    Clin Cancer Res. 2026 Jan 29. doi: 10.1158/1078-0432.CCR-25-3566.
    >> Share

  9. QU S, Pan Q, Zhang X, Wang J, et al
    Redefining Treatment Paradigms for Glioma in Adolescents and Young Adults: Population-Based Evidence for Molecular Classification.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2496.
    >> Share

    December 2025
  10. AHLUWALIA MS, Solomon S, Patel SP, Sarfraz Z, et al
    Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609).
    Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2900.
    >> Share

    November 2025
  11. BARBATO MI, Barone AK, Aungst SL, Miller CP, et al
    FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
    Clin Cancer Res. 2025;31:4412-4418.
    >> Share

    October 2025
  12. BAKHSHINYAN D, Custers S, Escudero L, Suk Y, et al
    Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance.
    Clin Cancer Res. 2025 Oct 15. doi: 10.1158/1078-0432.CCR-24-4010.
    >> Share

  13. MARIANI CL, Wachsmuth LP, Bramall AN, Meritet DM, et al
    Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs.
    Clin Cancer Res. 2025;31:4372-4382.
    >> Share

    August 2025
  14. FENG Y, Haupt B, Huynh TT, Meshaw R, et al
    Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms.
    Clin Cancer Res. 2025;31:3537-3549.
    >> Share

  15. HABASHY KJ, Synold TW, Feng Y, Gomez C, et al
    Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.
    Clin Cancer Res. 2025;31:3562-3570.
    >> Share

  16. VOLOVETZ J, Buchwald LV, Straede K, Kjaer A, et al
    The importance of integrating surgical resection into preclinical glioblastoma modeling.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0788.
    >> Share

  17. FAROUK SAIT S, O'Donohue TJ, Bale T, Bowman A, et al
    Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
    Clin Cancer Res. 2025;31:3285-3295.
    >> Share

    July 2025
  18. ZHANG N, Wu X, Yang L, Xiao F, et al
    Editor's Note: FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51.
    Clin Cancer Res. 2025;31:3098.
    >> Share

  19. ZHOU F, Sun Y, Chen X, Wu D, et al
    UBE2T-mediated HP1alpha ubiquitination enhances nucleolar function and promotes the progression of IDH1/TP53-mutant glioma.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-25-0261.
    >> Share

  20. VAUBEL RA, Zhang W, Oh JH, Mladek AC, et al
    Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma.
    Clin Cancer Res. 2025 Jul 1. doi: 10.1158/1078-0432.CCR-25-0244.
    >> Share

  21. VAN SCHAIK TA, Chen KS, Kanaya N, Moreno-Lama L, et al
    Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation.
    Clin Cancer Res. 2025;31:2793-2813.
    >> Share

    June 2025
  22. YU B, Kline C, Hoare O, Jung J, et al
    Measles oncolytic virus as an immunotherapy for recurrent/refractory pediatric medulloblastoma and atypical teratoid rhabdoid tumor: results from PNOC005.
    Clin Cancer Res. 2025 Jun 20. doi: 10.1158/1078-0432.CCR-24-3721.
    >> Share

  23. NIA HT, Datta M, Kumar AS, Siri S, et al
    Solid stress estimations via intraoperative 3D navigation in patients with brain tumors.
    Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-4159.
    >> Share

  24. KIM AR, Jeon SH, Park J, Kim ES, et al
    Co-blockade of TGFbeta and PD-1 reinvigorates glioblastoma-infiltrating CD8+ T cells that characteristically upregulate TGFbetaR expression.
    Clin Cancer Res. 2025 Jun 3. doi: 10.1158/1078-0432.CCR-24-2184.
    >> Share

  25. BHANJA D, Zhu J, Wilding H, Benavides-Vasquez J, et al
    A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy.
    Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-24-2681.
    >> Share

  26. RITZMANN TA, Hodgkinson R, Shanmugavadivel S
    Neither small adults nor big children: Doing better for TYAs with brain tumors.
    Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-25-1007.
    >> Share

    May 2025
  27. BEICHERT J, Hoffmann DC, Winkler F, Ratliff M, et al
    Innovative Therapeutic Strategies Targeting the Network Architecture of Glioblastoma.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0018.
    >> Share

  28. GREEN AL, Minard CG, Liu X, Safgren SL, et al
    Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial.
    Clin Cancer Res. 2025;31:1587-1595.
    >> Share

    April 2025
  29. FIORICA PN, Golmard L, Kim J, Bao R, et al
    Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.
    Clin Cancer Res. 2025;31:1491-1503.
    >> Share

  30. PERRINO MR, Jongmans MCJ, Tomlinson GE, Greer MC, et al
    Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis.
    Clin Cancer Res. 2025;31:1400-1406.
    >> Share

    March 2025
  31. ZHOU W, Yue Q, Yuan Y, Huang Q, et al
    Visualization of P2X7 Receptors in Living Human Gliomas: an 18F-GSK1482160 PET Imaging and Neuropatholopy Study.
    Clin Cancer Res. 2025 Mar 17. doi: 10.1158/1078-0432.CCR-24-2830.
    >> Share

  32. PEREIRA R, Mackay A, Grabovska Y, Bradley A, et al
    The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populations.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-1256.
    >> Share

    February 2025
  33. ALI MF, Riviere-Cazaux C, Johnson SH, Salvatori R, et al
    Personalized tumor-specific amplified DNA junctions in peripheral blood of patients with glioblastoma.
    Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-3233.
    >> Share

  34. LAMOUREUX AA, Fisher MJ, Lemelle L, Pfaff E, et al
    Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.
    Clin Cancer Res. 2025;31:561-572.
    >> Share

    January 2025
  35. TILL JE, Seewald NJ, Yazdani Z, Wang Z, et al
    Corticosteroid-dependent association between prognostic peripheral blood cell-free DNA levels and neutrophil-mediated NETosis in patients with glioblastoma.
    Clin Cancer Res. 2025 Jan 31. doi: 10.1158/1078-0432.CCR-24-3169.
    >> Share

  36. STEFAN D, Lesueur P, Lequesne J, Feuvret L, et al
    Olaparib, temozolomide and concomitant radiotherapy for partially or biopsy-only glioblastoma first-line treatment: results from the OLA-TMZ-RTE-01 phase 1 study.
    Clin Cancer Res. 2025 Jan 30. doi: 10.1158/1078-0432.CCR-24-2974.
    >> Share

  37. LEE EQ, Alexander BM, Romo CG, Supko JG, et al
    Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-2311.
    >> Share

  38. SINGH S, Bradford D, Chatterjee S, Li X, et al
    FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
    Clin Cancer Res. 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439.
    >> Share

  39. MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al
    Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
    Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977.
    >> Share

    December 2024
  40. FISCHER GM, Lamba N, Vogelzang J, Aizer A, et al
    Genomic profiling reveals SMARCA4 mutations are associated with shorter overall and intracranial progression free survival in melanoma brain metastasis patients.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-0301.
    >> Share

  41. RIVIERE-CAZAUX C, Dong X, Mo W, Kumar R, et al
    Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA.
    Clin Cancer Res. 2024 Dec 23. doi: 10.1158/1078-0432.CCR-24-1814.
    >> Share

  42. OLOW A, Mueller S, Yang X, Hashizume R, et al
    Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Clin Cancer Res. 2024;30:5494.
    >> Share

    November 2024
  43. IWAMOTO FM, Tanguturi SK, Nayak L, Wang TJ, et al
    Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1629.
    >> Share

  44. TOBOCHNIK S, Regan MS, Dorotan MKC, Reich D, et al
    Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma.
    Clin Cancer Res. 2024 Nov 5:OF1-OF9. doi: 10.1158/1078-0432.CCR-24-1849.
    >> Share

    October 2024
  45. CHAMSEDDINE I, Shah K, Lee H, Ehret F, et al
    Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.
    Clin Cancer Res. 2024;30:4424-4433.
    >> Share

    September 2024
  46. GROMMES C, Nandakumar S, Schaff LR, Gavrilovic I, et al
    A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Clin Cancer Res. 2024;30:4005-4015.
    >> Share

  47. RIXE O, Villano JL, Wesolowski R, Noonan AM, et al
    A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas.
    Clin Cancer Res. 2024 Sep 12. doi: 10.1158/1078-0432.CCR-24-1721.
    >> Share

  48. VAN DER VAART T, Wijnenga MMJ, van Garderen K, Dubbink HJ, et al
    Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study.
    Clin Cancer Res. 2024;30:3837-3844.
    >> Share

  49. GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al
    A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161.
    >> Share

    August 2024
  50. SUROV A, Borggrefe J
    Translational Imaging in Cerebral Tumors.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-2013.
    >> Share

  51. KARSCHNIA P, Tonn JC, Cahill DP
    The infiltrative margins in glioblastoma: important is what has been left behind.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1819.
    >> Share

  52. BARTOS LM, Quach S, Zenatti V, Kirchleitner SV, et al
    Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome.
    Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-1563.
    >> Share

  53. PASCUAL-PASTO G, McIntyre B, Giudice AM, Alikarami F, et al
    Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.
    Clin Cancer Res. 2024;30:3578-3591.
    >> Share

  54. LEE MD, Jain R, Galbraith K, Chen A, et al
    T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.
    Clin Cancer Res. 2024;30:3512-3519.
    >> Share

    July 2024
  55. GREWAL EP, Richardson LGK, Sun J, Ramapriyan R, et al
    Mutant IDH modulates suppressive myeloid populations in malignant glioma.
    Clin Cancer Res. 2024 Jul 23. doi: 10.1158/1078-0432.CCR-24-1056.
    >> Share

  56. REINECKE D, Ruess D, Meissner AK, Furtjes G, et al
    Streamlined intraoperative brain tumor classification and molecular subtyping in stereotactic biopsies using stimulated Raman histology and deep learning.
    Clin Cancer Res. 2024 Jul 8. doi: 10.1158/1078-0432.CCR-23-3842.
    >> Share

  57. GRAILLON T, Romanet P, Camilla C, Gelin C, et al
    A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1.
    Clin Cancer Res. 2024;30:2835-2845.
    >> Share

    June 2024
  58. GAO M, Liu Z, Zang H, Wu X, et al
    A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multi-Parametric MRI.
    Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-24-0150.
    >> Share

  59. AHLUWALIA MS, Ozair A, Drappatz J, Ye X, et al
    Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-4098.
    >> Share

  60. PARK YW, Choi KS, Foltyn-Dumitru M, Brugnara G, et al
    Incorporating Supramaximal Resection into Survival Stratification of IDH-Wildtype Glioblastoma: A Refined Multi-institutional Recursive Partitioning Analysis.
    Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-23-3845.
    >> Share

    May 2024
  61. JAIN S, Griffith JI, Porath KA, Rathi S, et al
    Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
    Clin Cancer Res. 2024 May 14. doi: 10.1158/1078-0432.CCR-24-0426.
    >> Share

  62. NASSER AM, Melamed L, Wetzel E, Chang CC, et al
    CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition.
    Clin Cancer Res. 2024 May 8. doi: 10.1158/1078-0432.CCR-24-0562.
    >> Share

  63. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Editor's Note: Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNbeta in Glioblastomas.
    Clin Cancer Res. 2024;30:1993.
    >> Share

    April 2024
  64. ABDULLAH KG
    Classifying glioma via liquid biopsy--progress towards an unmet clinical need.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0423.
    >> Share

  65. JOHANNS TM, Garfinkle EAR, Miller KE, Livingstone AJ, et al
    Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma.
    Clin Cancer Res. 2024 Apr 19. doi: 10.1158/1078-0432.CCR-23-3077.
    >> Share

  66. GRIESINGER AM, Calzadilla AJ, Grimaldo E, Donson AM, et al
    Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma.
    Clin Cancer Res. 2024;30:1544-1554.
    >> Share

  67. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    >> Share

  68. HANSFORD JR, Das A, McGee RB, Nakano Y, et al
    Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.
    Clin Cancer Res. 2024 Apr 4. doi: 10.1158/1078-0432.CCR-23-4033.
    >> Share

  69. LYNCE F, Lin NU
    From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
    Clin Cancer Res. 2024;30:1217-1219.
    >> Share

  70. STANISZEWSKA AD, Pilger D, Gill SJ, Jamal K, et al
    Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
    Clin Cancer Res. 2024;30:1338-1351.
    >> Share

    March 2024
  71. CICCONE R, Quintarelli C, Camera A, Pezzella M, et al
    GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
    Clin Cancer Res. 2024 Mar 29. doi: 10.1158/1078-0432.CCR-23-1880.
    >> Share

  72. DESAI PB, Karve A, Zawit M, Arora P, et al
    A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
    Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3341.
    >> Share

  73. SCHRECK KC, Strowd RE, Nabors LB, Ellingson BM, et al
    Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.
    Clin Cancer Res. 2024 Mar 6. doi: 10.1158/1078-0432.CCR-23-3241.
    >> Share

    February 2024
  74. FANGUSARO J, Avery RA, Fisher MJ, Packer RJ, et al
    Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
    Clin Cancer Res. 2024 Feb 15. doi: 10.1158/1078-0432.CCR-23-3386.
    >> Share

  75. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
    Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Response.
    Clin Cancer Res. 2024;30:639.
    >> Share

  76. MANDONNET E
    Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Letter.
    Clin Cancer Res. 2024;30:638.
    >> Share

    January 2024
  77. ISER F, Hinz F, Hoffmann DC, Grassl N, et al
    Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2907.
    >> Share

  78. HABASHY KJ, Dmello C, Chen L, Arrieta VA, et al
    Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2367.
    >> Share

  79. LIM-FAT MJ, Iorgulescu JB, Rahman R, Bhave V, et al
    Clinical and genomic predictors of adverse events in newly diagnosed glioblastoma.
    Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3018.
    >> Share

  80. MARGOLIN KA
    The Dance Between Tumor Molecular Biology and Antitumor Immune Response.
    Clin Cancer Res. 2024;30:257-259.
    >> Share

  81. PETRONEK MS, Monga V, Bodeker KL, Kwofie M, et al
    Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.
    Clin Cancer Res. 2024;30:283-293.
    >> Share

  82. HAYASHI T, Tateishi K, Matsuyama S, Iwashita H, et al
    Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
    Clin Cancer Res. 2024;30:116-126.
    >> Share

  83. CUI X, Wang Q, Liu X, Kang C, et al
    Levetiracetam: a potent sword against microglia polarization in gliomas.
    Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3322.
    >> Share

    December 2023
  84. GALBO PM, Madsen AT, Liu Y, Peng M, et al
    Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma.
    Clin Cancer Res. 2023 Dec 7. doi: 10.1158/1078-0432.CCR-23-0493.
    >> Share

  85. SLOAN AR, Thapliyal M, Lathia JD
    New T-cell therapies for brain metastasis, CD133 in the driver's seat.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-3051.
    >> Share

  86. KURZ SC, Zan E, Cordova C, Troxel AB, et al
    Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2533.
    >> Share

  87. KAMSON DO, Puri S, Sang Y, Shi MJ, et al
    Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
    Clin Cancer Res. 2023;29:4863-4869.
    >> Share

  88. DAS A, Tabori U, Sambira Nahum LC, Collins NB, et al
    Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
    Clin Cancer Res. 2023;29:4770-4783.
    >> Share

    November 2023
  89. NABAVIZADEH A, Bagley SJ
    Exploiting iron metabolism as a therapeutic vulnerability in glioblastoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-3027.
    >> Share

  90. ARRIETA VA, Duerinck J, Burdett KB, Habashy KJ, et al
    ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1889.
    >> Share

  91. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
    Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma.
    Clin Cancer Res. 2023 Nov 1. doi: 10.1158/1078-0432.CCR-23-1180.
    >> Share

    October 2023
  92. LI J, Hu H, Qin G, Bai F, et al
    Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-2213.
    >> Share

  93. GUO X, Qiu W, Li B, Qi Y, et al
    Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0430.
    >> Share

  94. GOTTARDO NG, Gajjar A
    Verschlimmbesserung: Craniospinal Radiotherapy is Essential in WNT Medulloblastoma Patients.
    Clin Cancer Res. 2023 Oct 12. doi: 10.1158/1078-0432.CCR-23-2331.
    >> Share

  95. KIELISZEK AM, Mobilio D, Upreti D, Bloemberg D, et al
    Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases.
    Clin Cancer Res. 2023 Oct 3. doi: 10.1158/1078-0432.CCR-23-1735.
    >> Share

    September 2023
  96. LUKAS RV, Horbinski C
    Glioma Response to IDH Inhibition: Real-World Experience.
    Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164.
    >> Share

  97. JOHNSON M, Bell A, Lauing KL, Ladomersky E, et al
    Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-0834.
    >> Share

  98. FERMI V, Warta R, Wollner A, Lotsch C, et al
    Effective reprogramming of patient-derived M2-polarized glioblastoma-associated microglia/macrophages by treatment with GW2580.
    Clin Cancer Res. 2023 Sep 8. doi: 10.1158/1078-0432.CCR-23-0576.
    >> Share

    August 2023
  99. KINSLOW CJ, Rae AI, Taparra K, Kumar P, et al
    MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1295. doi: 10.1158/1078-0432.CCR-23-1295.
    >> Share

  100. NAYYAR N, de Sauvage MA, Chuprin J, Sullivan EM, et al
    CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.
    Clin Cancer Res. 2023 Aug 23:CCR-23-0433. doi: 10.1158/1078-0432.CCR-23-0433.
    >> Share

  101. BARBATO MI, Nashed J, Bradford D, Ren Y, et al
    FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.
    >> Share

  102. TEW BY, Kalfa AJ, Yang Z, Hurth KM, et al
    ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis.
    Clin Cancer Res. 2023 Aug 16:CCR-23-0290. doi: 10.1158/1078-0432.CCR-23-0290.
    >> Share

  103. SRINIVASAN ES, Liu Y, Odion RA, Chongsathidkiet P, et al
    Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors.
    Clin Cancer Res. 2023;29:3214-3224.
    >> Share

  104. ELLINGSON BM, Hagiwara A, Morris CJ, Cho NS, et al
    Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1235. doi: 10.1158/1078-0432.CCR-23-1235.
    >> Share

    July 2023
  105. COHEN KJ, Munjapara V, Aguilera D, Castellino RC, et al
    A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma.
    Clin Cancer Res. 2023 Jul 27:CCR-23-0348. doi: 10.1158/1078-0432.CCR-23-0348.
    >> Share

  106. LAL B, Kulkarni A, McDermott J, Rais R, et al
    Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0673. doi: 10.1158/1078-0432.CCR-23-0673.
    >> Share

  107. KESSLER T, Schrimpf D, Doerner L, Hai L, et al
    Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0926. doi: 10.1158/1078-0432.CCR-23-0926.
    >> Share

  108. XU Q, Huang K, Meng X, Weng Y, et al
    Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2023 Jul 21:CCR-23-0388. doi: 10.1158/1078-0432.CCR-23-0388.
    >> Share

  109. YUAN W, Zhang Q, Gu D, Lu C, et al
    Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages.
    Clin Cancer Res. 2023 Jul 13:CCR-22-3273. doi: 10.1158/1078-0432.CCR-22-3273.
    >> Share

    June 2023
  110. LY KI, Richardson LG, Liu M, Muzikansky A, et al
    Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0203. doi: 10.1158/1078-0432.CCR-23-0203.
    >> Share

  111. FOOTE MB, Argiles G, Rousseau B, Segal NH, et al
    Facts and hopes in colorectal cancer immunotherapy.
    Clin Cancer Res. 2023 Jun 16:CCR-22-2176. doi: 10.1158/1078-0432.CCR-22-2176.
    >> Share

  112. CHITTIBOINA P, Mandal D, Bugarini A, Asuzu DT, et al
    Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
    Clin Cancer Res. 2023;29:2199-2209.
    >> Share

  113. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    >> Share

  114. MACK SC, Bertrand KC
    A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
    Clin Cancer Res. 2023 Jun 1:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-0472.
    >> Share

    May 2023
  115. SHI L, Chen H, Chen K, Zhong C, et al
    The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma.
    Clin Cancer Res. 2023 May 30:CCR-22-3971. doi: 10.1158/1078-0432.CCR-22-3971.
    >> Share

  116. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
    Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
    Clin Cancer Res. 2023 May 25:OF1-OF5. doi: 10.1158/1078-0432.CCR-23-0009.
    >> Share

  117. MACK SC, Bertrand KC
    A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
    Clin Cancer Res. 2023 May 15:CCR-23-0472. doi: 10.1158/1078-0432.CCR-23-0472.
    >> Share

  118. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
    Taming Glioblastoma in 'Real Time': Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology".
    Clin Cancer Res. 2023 May 9:CCR-23-0009. doi: 10.1158/1078-0432.CCR-23-0009.
    >> Share

    April 2023
  119. THIESLER H, Gretenkort L, Hoffmeister L, Albers I, et al
    Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients.
    Clin Cancer Res. 2023 Apr 14:CCR-22-1488. doi: 10.1158/1078-0432.CCR-22-1488.
    >> Share

  120. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
    Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
    Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016